First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy

Brachytherapy

Volumn 12, Issue 4, 2013, Pages 368-374

  Beydoun, Nadine ^a   Bucci, Joseph A ^a   Chin, Yaw S ^a   Malouf, David ^a   Enari, Ese ^a   Painter, Samuel D ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Polyethylene glycol hydrogel; Seed brachytherapy; Spacing agent; Transperineal spacer

Indexed keywords

ANESTHETIC AGENT; IODINE 125; MACROGOL;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DOSIMETRY; FEASIBILITY STUDY; HUMAN; HYDROGEL; MALE; NATIONAL HEALTH ORGANIZATION; PAIN; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIOTHERAPY EQUIPMENT; RECTUM DISEASE; TRANSRECTAL ULTRASONOGRAPHY;

AGED; BRACHYTHERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTUM;

EID: 84879463678     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2013.01.164     Document Type: Article

References (25)

1. Merrick G.S., Butler W.M., Wallner K.E., et al. Long-term urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 56:454-461.
2. Al-Mamgani A., Van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72:980-988.
3. Dearnley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
4. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M. D. Anderson randomized dose escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
5. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 2005, 23:1192-1199.
6. Zietman A.L., DeSilvio M., Slater J.D., et al. Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate. JAMA 2005, 294:1233-1239.
7. Al-Mamgani A., Heemsbergen W.D., Peeters S.T., et al. Role of intensity-modulated radiotherapy in reducing toxicity in dose escalation for localized prostate cancer. Int J Radiat Oncol Biol Phys 2009, 73:685-691.
8. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.
9. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: Dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002, 54:1314-1321.
10. Tran A., Wallner K., Merrick G., et al. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 63:150-154.
11. Merrick G.S., Butler W.M., Wallner K., et al. Late rectal function afterprostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 57:42-48.
12. Howard A., Wallner K., Han B., et al. Clinical course and dosimetry of rectal fistulas after prostate brachytherapy. J Brachyther Int 2001, 17:37-42.
13. 125I prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003, 55:342-353.
14. Mueller A., Wallner K., Merrick G., et al. Perirectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 2004, 59:1047-1052.
15. Davis B.J., Horwitz E.M., Lee W.R., et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 2012, 11:6-19.
16. Wallner K., Roy J., Harrison L., et al. Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 1995, 32:465-471.
17. Susil R.C., McNutt T.R., DeWeese T.L., et al. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:1251-1258.
18. Wilder R.B., Barme G.A., Gilbert R.F., et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:824-830.
19. Prada P.J., Gonzalez H., Menéndez C., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8:210-217.
20. Prada P.J., Fernandez J., Martinez A.A., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:95-102.
21. Noyes W.R., Hosford C.C., Schultz S.E. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 2012, 82:1918-1922.
22. Pinkawa M., Corral N.E., Caffaro M., et al. Application of a spacer gel to optimise three-dimensional conformal and intensity modulated radiotherapy for prostate cancer. Radiother Oncol 2011, 100:436-441.
23. Blasko J.C., Mate T., Sylvester J.E., et al. Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes. Semin Radiat Oncol 2002, 12:81-94.
24. National Cancer Institute Common Terminology Criteria for Adverse Events. Available at: . Accessed February 10,2012. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40.
25. Snyder K.M., Stock R.G., Hong S.M., et al. Defining the risk of developing grade 2 proctitis following (125)I prostate brachytherapy using a rectal dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2001, 50:335-341.